(Q35338479)

7 August 2017

1 reference

title

Endocrine therapy for advanced breast cancer: a review (English)

1 reference

7 August 2017

1 reference

H. B. Muss

1

1 reference

PubMed ID

1382723

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1382723

20 September 2022

language of work or name

English

0 references

publication date

1 January 1992

1 reference

Breast Cancer Research and Treatment

7 August 2017

1 reference

7 August 2017

21

1 reference

7 August 2017

15-26

1 reference

7 August 2017

1

1 reference

https://scigraph.springernature.com/pub.10.1007/bf01811960

7 August 2017

0 references

cites work

The relationship between c-erbB-2 expression, S-phase fraction and prognosis in breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FBF01811960

Combination chemotherapy compared to tamoxifen as initial therapy for stage IV breast cancer in elderly women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01811960

Prospective, randomized clinical trial of two different high dosages of medroxyprogesterone acetate (MAP) in the treatment of metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01811960

The use of an LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01811960

The mechanism of hormone-sensitive breast cancer progression on antiestrogen therapy. Implications for treatment and protocol planning

21 January 2018

1 reference

12 December 2020

High Dose Medroxyprogesterone Acetate (MPA) Treatment in Metastatic Carcinoma of the Breast: A Dose-Response Evaluation

1 reference

12 December 2020

Comparison of tamoxifen and hypophysectomy in breast cancer treatment

1 reference

12 December 2020

Principles of therapy in advanced breast cancer

1 reference

12 December 2020

Node-negative breast cancer: prognostic subgroups defined by tumor size and flow cytometry.

1 reference

12 December 2020

[Bromocriptine in chemotherapy-resistant, metastatic breast cancer. Results of the GO-MC-BROMO 2/82 AIO Study]

1 reference

12 December 2020

Treatment of advanced breast cancer with progestins

1 reference

12 December 2020

Cellular distribution patterns of estrogen receptor in human breast cancer

1 reference

12 December 2020

Treatment of advanced postmenopausal breast cancer with an aromatase inhibitor, 4-hydroxyandrostenedione: phase II report

1 reference

12 December 2020

Proliferative activity of primary breast cancer and of synchronous lymph node metastases evaluated by [3H]-thymidine labelling index.

1 reference

12 December 2020

Distribution, frequency, and quantitative analysis of estrogen, progesterone, androgen, and glucocorticoid receptors in human breast cancer

1 reference

12 December 2020

Aromatase inhibitors as new endocrine therapy for breast cancer

1 reference

12 December 2020

Tamoxifen (Nolvadex) versus adrenalectomy in metastatic breast cancer

1 reference

12 December 2020

The clinical biology of hormone-responsive breast cancer

1 reference

12 December 2020

Action of oral methylprednisolone in terminal cancer patients: a prospective randomized double-blind study

1 reference

12 December 2020

Growth control of normal and malignant breast epithelium

1 reference

12 December 2020

A randomized trial comparing surgical adrenalectomy with aminoglutethimide plus hydrocortisone in women with advanced breast cancer

1 reference

12 December 2020

Endocrine effects of combined somatostatin analog and bromocriptine therapy in women with advanced breast cancer

1 reference

12 December 2020

Progestational agents in advanced breast cancer: an overview

1 reference

12 December 2020

A randomized trial of chemotherapy and hormonal therapy in advanced breast cancer

1 reference

12 December 2020

Phase II trials with toremifene in advanced breast cancer: a review

1 reference

12 December 2020

Heterogeneous estrogen receptor levels detected via multiple microsamples from individual breast cancers

1 reference

12 December 2020

Tamoxifen rechallenge: response to tamoxifen following relapse after adjuvant chemohormonal therapy for breast cancer

1 reference

12 December 2020

High- versus standard-dose megestrol acetate in women with advanced breast cancer: a phase III trial of the Piedmont Oncology Association

1 reference

12 December 2020

Tamoxifen flare in advanced breast cancer

1 reference

12 December 2020

The use of endocrine therapy

1 reference

12 December 2020

Tamoxifen-citrate counteracts the antitumor effects of cytotoxic drugs in vitro.

1 reference

12 December 2020

Danazol in the treatment of women with metastatic breast cancer

1 reference

12 December 2020

Antiestrogen therapy for breast cancer: Current strategies and potential causes for therapeutic failure

1 reference

12 December 2020

Tamoxifen therapy of metastatic breast cancer.

1 reference

12 December 2020

Hormone-induced tumor flare

1 reference

12 December 2020

The use of ketoconazole as an inhibitor of steroid production

1 reference

12 December 2020

Phase II study of flutamide in patients with metastatic breast cancer. A National Cancer Institute of Canada Clinical Trials Group study

1 reference

12 December 2020

A phase I/II investigation of trioxifene mesylate in advanced breast cancer. Clinical and endocrinologic effects

1 reference

12 December 2020

Danazol treatment for advanced breast cancer

1 reference

12 December 2020

Multicenter study of trilostane: a new hormonal agent in advanced postmenopausal breast cancer

1 reference

12 December 2020

Aminoglutethimide in the treatment of advanced breast cancer

1 reference

12 December 2020

Corticosteroids for elderly patients with breast cancer

1 reference

12 December 2020

On the role of additive hormone monotherapy with tamoxifen, medroxyprogesterone acetate and aminoglutethimide, in advanced breast cancer

1 reference

12 December 2020

The response of breast cancer patients with bone pain to L-dopa

1 reference

12 December 2020

Diethylstilbestrol: recommended dosages for different categories of breast cancer patients. Report of the Cooperative Breast Cancer Group

1 reference

12 December 2020

The relation of flow cytometry to clinical and biologic characteristics in women with node negative primary breast cancer

1 reference

12 December 2020

High dose versus low dose medroxyprogesterone acetate: a randomized trial in advanced breast cancer

1 reference

12 December 2020

A phase II study with danazol in metastatic breast cancer

1 reference

12 December 2020

An overview of megestrol acetate for the treatment of advanced breast cancer

1 reference

12 December 2020

Combination hormonal therapy with tamoxifen plus fluoxymesterone versus tamoxifen alone in postmenopausal women with metastatic breast cancer. An updated analysis

1 reference

12 December 2020

European early phase II dose-finding study of droloxifene in advanced breast cancer

1 reference

12 December 2020

Clinical significance of tamoxifen withdrawal response

1 reference

12 December 2020

Aminoglutethimide in the treatment of premenopausal patients with metastatic breast cancer

1 reference

12 December 2020

Treatment of breast cancer with different antiprogestins: preclinical and clinical studies

1 reference

12 December 2020

High-dose megestrol acetate in the treatment of advanced breast cancer.

1 reference

12 December 2020

Endocrine treatment for breast cancers: biological rationale and current progress

1 reference

12 December 2020

Chemotherapy and hormonal therapy in combination

1 reference

12 December 2020

The role of progestins and progesterone receptors in the treatment of breast cancer

1 reference

12 December 2020

Randomized trial of low- versus high-dose medroxyprogesterone acetate in the induction treatment of postmenopausal patients with advanced breast cancer

1 reference

12 December 2020

4-Hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer

1 reference

12 December 2020

Cell kinetics as a prognostic indicator in node-negative breast cancer

1 reference

12 December 2020

Danazol treatment of advanced breast cancer

1 reference

12 December 2020

A randomized trial in postmenopausal patients with advanced breast cancer comparing endocrine and cytotoxic therapy given sequentially or in combination. The Australian and New Zealand Breast Cancer Trials Group, Clinical Oncological Society of Aust

1 reference

12 December 2020

Clinical use of aromatase inhibitors in the treatment of breast cancer

1 reference

12 December 2020

Trilostane therapy for advanced breast cancer

1 reference

12 December 2020

Additive hormonal therapy in women with advanced breast cancer

1 reference

12 December 2020

Oestrogen receptors, sites of metastatic disease and survival in recurrent breast cancer

1 reference

12 December 2020

Aminoglutethimide as treatment of postmenopausal women with advanced breast carcinoma

1 reference

12 December 2020

Aminoglutethimide-induced hematologic toxicity: worldwide experience

1 reference

12 December 2020

Endocrine ablative therapy of metastatic breast cancer

1 reference

12 December 2020

Trilostane in the treatment of advanced breast cancer

1 reference

12 December 2020

A comparative trial of transsphenoidal hypophysectomy and estrogen suppression with aminoglutethimide in advanced breast cancer

1 reference

12 December 2020

Heterogeneity in hormone receptor status in primary and metastatic breast cancer

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF01811960

1 reference

7 August 2017

1 reference

PubMed ID

1382723